Delivery Order SPE2DB24D2102-SPE2DB26FJHME
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens, with a ceiling value of $1,548.76. This is a firm fixed price delivery order with an ultimate completion date of October 16, 2025, executed without a set-aside designation, indicating competitive award. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $15,528.32 to AmerisourceBergen Drug Corp for the supply of Humulin R 500 Unit/ML KwikPen 3ML insulin pens. This non-competitive delivery order carries a firm fixed price and is scheduled for completion by September 8, 2025. The award was made to AmerisourceBergen's Corporate Office division, headquartered in Conshohocken, Pennsylvania, where the products will be supplied from. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens, with a contract value of $6,473.57 and an ultimate completion date of August 28, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing federal contract vehicle. The place of performance is listed as AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens at a firm fixed price of $2,196.22, with ultimate completion scheduled for October 20, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens, valued at $4,646.28. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by August 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Humulin R 500 Unit/mL KwikPen insulin pens (3 mL) with a ceiling value of $17,358.71 under a firm fixed-price arrangement. The award, issued on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a direct purchase of pharmaceutical supplies with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Humulin R 500 Unit/ML KwikPen 3ML insulin pens, valued at $12,000.90. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,876.19 to AmerisourceBergen Drug Corp for the supply of Humulin R 500 Unit/mL KwikPen insulin pens (3mL). The contract employs firm fixed price terms and is scheduled for completion by September 19, 2025, one day after the award date of September 18, 2025. This non-set-aside delivery order is being fulfilled from the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens, valued at $3,097.52. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $26,828.48 to AmerisourceBergen Drug Corp for Humulin R 500 Unit/ML KwikPen 3ML insulin pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 31, 2025, and represents a single transaction under AmerisourceBergen's existing contract vehicle with DLA. The pharmaceutical product will be delivered to the company's distribution center in Conshohocken, Pennsylvania. As a non-set-aside...
- SPE2DB24D2102Indefinite Delivery Contract
- SPE2DB24D2102-SPE2DB26FJHMEDelivery Order
This delivery order awards AmerisourceBergen Drug Corp a $4,266.67 firm fixed price contract for Humulin R 500 Unit/ML KwikPen 3ML insulin pens, with an ultimate completion date of October 29, 2025. The award, issued by the Defense Logistics Agency (DLA), represents a non-competitive delivery order placed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical vendor within the federal medical supply chain, supporting military and veteran healthcare systems. The Humulin R insulin supply falls within the company's broader portfolio of diabetes management medications delivered through its comprehensive global pharmaceutical support vehicle. As a child contract under the larger SPE2DX IDC, this order leverages the established pricing and terms negotiated under the prime indefinite delivery contract, enabling the DLA to efficiently procure essential pharmaceutical products for military medical operations and personnel healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 10/28/25 |